China National Intellectual Property Administration

IP1894537P

Unitalen Attorneys At Law 7th Floor, Scitech Place, No. 22, Jian Guo Men Wai Ave., Chao Yang District, Beijing 100004,P. R. China

Mailing Date:
August 3, 2022

Application No.: 201780022257.9

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MEDCARA

PHARMACEUTICALS, LLC

Title: FORMULATIONS OF TESTOSTERONE AND METHODS OF TREATMENT THEREWITH

Notification for Going through Patent Registration Formalities

According to Rule 54 of the Implementing Regulations of the Chinese Patent Law and Announcement No. 272 of the CNIPA, the applicant is required to pay the following fee before **October 18, 2022.**

The 6th Annuity Fee: RMB 1200.00

Total Sum: RMB 1200.00

Amount of Paid Fee: Annuity Fee: RMB 0.00

If the above fee is paid by the applicant before the time limit, the CNIPA will register the grant of the patent on the Patent Register, issue a Patent Certificate and announce the grant of patent. The patent shall take effect as of the date of the announcement.

If the applicant fails to pay the above fee in full within the time limit, the applicant shall be deemed to have abandoned the entitlement to patent.

China National Intellectual Property Administration

IP1894537P

Applicant	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MEDCARA PHARMACEUTICALS, LLC	Mailing date	
Application No.	201780022257.9		
Title of the Invention	FORMULATIONS OF TESTOSTERONE AND METHODS OF TREATMENT THEREWITH	August 3, 2022	

Notification of Grant of Patent for Invention

1. In accordance with the provisions of Article 39 of Chinese Patent Law and Rule 54 of the Implementing Regulations under the Chinese Patent Law, patent right is granted to the above-identified application on the fact that no cause for rejecting the patent application has been found in the examination as to substance.

After receiving this notification, the applicant should complete relevant registration formalities in accordance with the requirements in the Notification on Patent Registration.

After the applicant has gone through the registration formalities within the prescribed time limit, the China National Intellectual Property Administration shall make a decision to grant a patent right for invention, issue the patent certificate, register and announce the same accordingly. If the time limit for the registration formalities is not met, the applicant shall be deemed to have abandoned the right to obtain the patent right.

		C	•	C
	The above-identified patent application for invention is granted a patent documents:; □Document(s) as to substance was directed to the Chinese translation of filed.	_		
	☑The following document(s):			
	Paragraphs <u>1-244</u> of the Specification, Attached Drawing(s), the Abstract a were submitted on <u>October 8, 2018</u> . Claims <u>1-62</u> , which were submitted on <u>July 19, 2022</u> .	nd the Drawi	ngs of Abst	ract, which
	 The title of the above-identified patent application for invention has ☑NOT been changed. ☐Been changed from the original one: 			
4.[☐ The applicant filed a "Declaration of Abandonment of Patent" for patent N after examination:	No	on	, and
	☐The procedure of abandonment of patent has been entered.			
	☐ The procedure of waiver of patent has not been entered, for the reason that was declared by the applicant and the present patent application for in invention-creation.	-		
5.	. □The Examiner has made <i>ex officio</i> the following amendment:			

6. No voluntary amendments of this application shall be accepted by this Office after the issue of this Notification.

Your Ref.:UTFB.P1105CN Our Ref.:IP1894537P

China National Intellectual Property Administration

Address: Receiving Section of the China National Intellectual Property Administration, No. 6 Tucheng Road West, Haidian District, Beijing.

Search Report

Patent Application No. 201780022257.9	Filing Date: March 2, 2017	Supplementary Search
Applicant: BOARD OF REGENTS, THE	Earliest Priority Date: March 2, 2016	
UNIVERSITY OF TEXAS SYSTEM		
No. of Claims: 62	Paragraph(s) of Description: 244+6	

IPC No. Determined by Examiner: A61K31/568, A61K47/14, A61K47/44, A61P25/24, A61P25/22,

A61P15/00

Search Record Information: US2013022674A1: obtained from search report of US family patents

EP1530965A1: obtained from search report of EP family patents

	Relevant Patent Documents						
Type	Type Country and Document Date Given by IPC No. Relevant Relevant						
	No. Given by Code [11]	Code [43] or [45]		Paragraph(s) and/or	Claim No.		
				Figure No.			
A	US2013022674A1	January 24, 2013	A61K31/568	Full text	1-62		
A	EP1530965A1	May 18, 2005	A61K9/107	Full text	1-62		

	Relevant Non-Patent Documents						
Туре	Title of Book (Including Edition and Volume)	Date of Publication	Name of Author and Name of Publisher	Relevant Page(s)	Relevant to claim No.		
Type	Title of Periodical or Abstract (Including Volume and Issue)	Date of Issue	Name of Author and Title of Article	Relevant Page(s)	Claim(s) Involved		

Directions for Filling out the Form:

- 1. The IPC number of the field actually searched by the examiner should be filled in terms of the class and/or the subclass.
- 2. For the titles of periodicals or other periodic publications, abbreviations conforming to generally acknowledged international practice may be used.
- 3. Categories of relevant documents:
 - X: a document that prejudices novelty or inventiveness;
 - Y: the document that when combined with other such documents cited in the search report, prejudices inventiveness;
 - A: the document defining the general state of the art;
 - R: the patent or patent application document belonging to identical invention-creation that was submitted to the Patent Office by any entity or individual on the date of filing;
 - P: intermediate document, that is the document published on dates falling between the filing date of the application being examined and the claimed priority date;
 - E: Conflicting application.

Examiner: ZHANG Qian

Examination Department: Pharmaceutical and Biological Invention Examination Department of Patent

Examination Cooperation Center of the Patent Office, SIPO, Beijing

Date: July 27, 2022



2022-10-18

100004

北京市朝阳区建外大街 22 号赛特广场 7 层 北京集佳知识产权代理有限公司

郑斌((8610) 59208888) 刘振佳((8610) 59208888)

发文目:

2022年08月03日





申请号或专利号: 201780022257.9

发文序号: 2022072901857440

申请人或专利权人: 得克萨斯州大学系统董事会 麦德卡拉制药有限责任公司

发明创造名称: 睾酮制剂以及用其治疗的方法

办理登记手续通知书

根据专利法实施细则第 54 条及国家知识产权局第 272 号公告的规定,申请人应当于 2022 年 10 月 18 日 之前缴纳以下费用:

第6年度年费

1200.0元

无费减 (减缴标记)

附已缴费用情况: 年费 0.0 元。

申请人按期缴纳上述费用的,国家知识产权局将在专利登记簿上登记专利权的授予,颁发专利证书,并予以公告。专利权自公告之日起生效。

申请人期满未缴纳或者未缴足上述费用的,视为放弃取得专利权的权利。

提示:

专利费用可以通过网上缴费系统在线缴纳,也可通过银行、邮局汇款或直接向代办处或国家知识产权局专利局面交。

网上缴费网址为 http://cponline.cnipa.gov.cn, 缴费人可按照相关要求登录网上缴费系统缴纳相关费用。

银行、邮局汇款及面交缴费的,缴费人可按属地就近的原则选择国家知识产权局专利局各代办处进行缴纳。代办处及国家知识产权局专利局地址信息,银行、邮局账户以及联系电话等信息可进入国家知识产权局官方网站进行查看。

汇款时应当准确写明申请号、费用名称及分项金额,也可通过专利缴费信息网上补充及管理系统(http://fee.cnipa.gov.cn)进行缴费信息的补充。不符合上述规定的视为未办理缴费手续。了解更多详细信息及要求,请进入 https://www.cnipa.gov.cn 查询。

缴费人可通过电子票据交付服务系统 http://pjonline.cnipa.gov.cn 及支付宝、微信的电子票夹小程序查询、下载相应电子票据。

审 查 员:自动审查

审查部门: 专利局初审及流程管理部

联系电话: 010-62356655



100004

北京市朝阳区建外大街 22 号赛特广场 7 层 北京集佳知识产权代理有限公司

郑斌((8610) 59208888) 刘振佳((8610) 59208888)

发文目:

2022年08月03日





申请号或专利号: 201780022257.9

发文序号: 2022072701223400

申请人或专利权人: 得克萨斯州大学系统董事会,麦德卡拉制药有限责任公司

发明创造名称: 睾酮制剂以及用其治疗的方法

授予发明专利权通知书

(进入国家阶段的 PCT 申请)

1. 根据专利法第39条及实施细则第54条的规定,上述发明专利申请经实质审查,没有发现驳回理由,现作出授予专利权的通知。

申请人收到本通知书后,还应当依照办理登记手续通知书的内容办理登记手续。

申请人按期办理登记手续后,国家知识产权局将作出授予专利权的决定,颁发发明专利证书,并予以登记和公告。期满未办理登记手续的,视为放弃取得专利权的权利。

法律、行政法规规定相应技术的实施应当办理批准、登记等手续的,应依照其规定办理。

- 2. 授予专利权的上述发明专利申请是以下列申请文件为基础的:
 - □原始提交的国际申请的中文文本或中文译文进行的。
 - ▽ 针对下列申请文件进行的:

2018年10月8日提交的说明书第1-244段、说明书附图、说明书摘要、摘要附图;

2022年7月19日提交的权利要求第1-62项。

- 3. 授予专利权的上述发明专利申请的名称:
 - 未变更。
 - □由 变更为上述发明创造名称。
- 4. □申请人于 年 月 日提交专利号为 的"放弃专利权声明",经审查:
 - □进入放弃专利权的程序。
 - 一未进入放弃专利权的程序。理由是:申请人声明放弃的专利与本发明专利申请不属于相同的发明创造。
- 5. | | 审查员依职权对申请文件修改如下:
- 注: 在本通知书发出后收到的申请人主动修改的申请文件,不予考虑。

审查员:张茜

审查部门: 专利审查协作北京中心医药生物 发明审查部

联系电话: 010-53961878



检索报告

申请号: 2017800222579	申请日: 20170302	补充检索
申请人: 得克萨斯州大学系统董事会	最早的优先权日: 20160302	
权利要求项数: 62	说明书段数: 244+6	

审查员确定的 IPC 分类号:A61K31/568,A61K47/14,A61K47/44,A61P25/24,A61P25/22,A61P15/00

检索记录信息: US2013022674A1: 来自美国同族的检索报告

EP1530965A1: 来自欧洲同族的检索报告

相 关 专 利 文 献						
类型	国别以及代码[11]	代码[43]或[45]	IPC 分类号	相关的段落	涉及的权	
	给出的文献号	给出的日期		和/或图号	利要求	
А	US2013022674A1	20130124	A61K31/568	全文	1-62	
А	EP1530965A1	20050518	A61K9/107	全文	1-62	



相关非专利文献					
类型	书名(包括版本号和卷号)	出版日期	 作者姓名和出版者名称 	相关页数	涉及的权利要求
类型	期刊或文摘名称 (包括卷号和期号)	发行日期	作者姓名和文章标题	相关页数	涉及的权利要求

表格填写说明事项:

- 1. 审查员实际检索领域的 IPC 分类号应当填写到大组和 / 或小组所在的分类位置。
- 2. 期刊或其它定期出版物的名称可以使用符合一般公认的国际惯例的缩写名称。
- 3. 相关文件的类型说明:
 - X: 一篇文件影响新颖性或创造性;
 - Y: 与本报告中的另外的 Y 类文件组合而影响创造性;
 - A: 背景技术文件;
 - R: 任何单位或个人在申请日向专利局提交的、属于同样的发明创造的专利或专利申请文件。
 - P: 中间文件, 其公开日在申请的申请日与所要求的优先权日之间的文件;
 - E: 抵触申请。

审 查 员: 张茜 2022年07月27日 审查部门: 专利审查协作北京中心医药生物发明审查部